Arca
Skip to content

Small lymphocytic lymphoma

Drug research and approvals for small lymphocytic lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 113 studies of small lymphocytic lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 15 drug trials for it since 2013, and FDA has 14 approved and 4 open orphan designations naming it.

  • Recruiting worldwide: 113
  • Trials authorized in Canada: 15
  • FDA orphan approvals: 14
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 113 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 15; search them all in Canada trials
Aug 11, 2026A single-arm, phase 2, open-label, multicenter study to evaluate nx-5948 in adults with relapsed/refractory (r/r) chronic lymphocytic leukemia (cll) or small…NX-5948NURIX THERAPEUTICS, INC.Pending
Dec 4, 2025A phase III, randomised, open-label, multicentre, study of surovatamig as consolidation therapy versus observation after first-line induction therapy in…SUROVATAMIG (AZD0486)AstraZeneca Pharmaceuticals LPOngoing
Sep 17, 2025A phase 3 randomized, open-label, multicenter study of sonrotoclax plus anti-cd20 antibody therapies versus venetoclax plus rituximab in patients with…SONROTOCLAX (BGB-11417) / OBINUTUZUMAB / RITUXIMAB / VENETOCLAXBeOne MedicinesPending
Mar 25, 2025A phase 3, open-label, randomized study of bgb-16673 compared to investigator's choice (idelalisib plus rituximab or bendamustine plus rituximab or venetoclax…TACABRUTIDEG (BGB-16673) / BENDAMUSTINE / IDELALISIB / RITUXIMAB / VENETOCLAXBeOne MedicinesPending
Nov 28, 2024An open-label, phase 1/2 study of jcar017 in subjects with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphomaBREYANZIBristol-Myers SquibbOngoing
Nov 22, 2024A phase 2, open-label, randomized study evaluating the efficacy and safety of 3 doses of pirtobrutinib in participants with relapsed or refractory chronic…PIRTOBRUTINIB (LY3527727)Eli LillyOngoing
Oct 24, 2023A phase 3, randomized study to compare nemtabrutinib versus comparator (investigator's choice of ibrutinib or acalabrutinib) in participants with untreated…NEMTABRUTINIB (MK-1026)Merck & Co. (MSD)Ongoing
May 31, 2023A phase 1, open-label, multicenter, dose escalation study of prt1419 injection as monotherapy or in combination with azacitidine or venetoclax in patients with…PRT1419 / VENETOCLAX / AZACITIDINEPRELUDE THERAPEUTICSClosed
Mar 30, 2023Phase I/ib study of tbi-2001 for patients with relapsed or refractory cd19+ b-cell lymphoma, chronic lymphocytic lymphoma (cll), small lymphocytic lymphoma…TBI-2001 / PROCYTOX / FLUDARABINE PHOSPHATE FOR INJECTIONDR. MARCUS BUTLER, UNIVERSITY HEALTH NETWORK ¿ PRINCESS MARGARET CANCER CENTREOngoing
Mar 9, 2023A phase 3, open-label, randomized study to compare the efficacy and safety of nemtabrutinib (mk-1026) plus venetoclax versus venetoclax plus rituximab in…NEMTABRUTINIB (MK-1026)Merck & Co. (MSD)Ongoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 18
Oct 2, 2026Jaypircatreatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known…Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and CompanyApproved
Dec 3, 2025Jaypircatreatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have…Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and CompanyApproved
Mar 14, 2024Breyanzitreatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have…Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyApproved
Dec 1, 2023Jaypircatreatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior…Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and CompanyApproved
Jan 19, 2023Brukinsatreatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)BeOne Medicines USA, Inc.Approved
Aug 4, 2022CalquenceTreatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)Acerta Pharma, LLC (a member of the AstraZeneca Group)Approved
Nov 21, 2019acalabrutinibCALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).Acerta Pharma, LLC (a member of the AstraZeneca Group)Approved
May 15, 2019VENCLEXTAVENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).AbbVie, IncApproved
Sep 24, 2018COPIKTRATreatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at…Secura Bio, Inc.Approved
Jun 8, 2018VENCLEXTAVENCLEXTA® (venetoclax) indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma…AbbVie, IncApproved
May 6, 2016IMBRUVICAIndicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and indicated for the…Pharmacyclics, LLCApproved
Dec 7, 2015BendekaTreatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with…Eagle Pharmaceuticals, Inc.Approved
Jul 23, 2014ZydeligZydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for…Gilead Sciences, Inc.Approved
Oct 31, 2008TreandaTreatment of Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a…Cephalon, Inc.Approved
Dec 7, 2020nemtabrutinibTreatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)ArQule, Inc., a wholly owned subsidiary of Merck Sharp & Dohme, LLCDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.